ScripThe years of effort and expense Abivax has put into advancing obefazimod for ulcerative colitis (UC) have paid off now that the French firm has presented stellar results from a pair of Phase III trial
ScripRoche’s recent Phase III failure for its anti-ST2 monoclonal antibody, astegolimab, in chronic obstructive pulmonary disease (COPD) is a blow not just for the firm but also for the fledgling drug clas
ScripAstraZeneca is the latest large pharma company to announce a major manufacturing investment in the US as the Trump administration threatens to slap tariffs on imports. The drugmaker said July 21 that
ScripSanofi has hit the acquisition trail again to buy the UK’s Vicebio and its next-generation vaccines in a deal that could be worth $1.6bn. The French drugmaker is paying $1.15bn upfront, with potential